ITM_Logo_Claim_RGB_high-res.png
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
September 06, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
ITM SE CBO Sebastian Marx
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
July 22, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...